Resilience
3115 Merryfield Row, Suite 200
San Diego, CA 92121
T: (888) 737-2460
E: contact@resilience.com
LinkedIn: https://www.linkedin.com/company/weareresilience
Twitter: https://twitter.com/incresilience
W: https://resilience.com

 

Company Description

Resilience is a technology-focused biomanufacturing CDMO dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell and gene therapy), from process development to drug substance and drug product manufacturing. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale.

By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions.

Company background

Resilience is leading the pursuit of novel medicines and large molecule drugs by remaking how they are developed and manufactured. The technology of manufacturing complex medicines hasn’t kept pace with the wave of scientific discoveries fueling them.

Resilience has responded to two major problems — serving as a biomanufacturing powerhouse for process and analytical development, drug substance, and drug product across established (Biologics, Vaccines) to emerging (Cell and Gene Therapy) modalities, as well as focusing on the development of next-generation manufacturing technology platforms to keep up with essential product developments and increase access to complex medicines.

Markets/Facilities

Resilience serves global customers through its sites located in six states across the United States, as well as in Canada.

Products/Capabilities

With a current portfolio of 50+ clients across its network, ranging from large pharma to small and mid-size pharmaceutical and biotechnology companies, as well as government and NGOs, Resilience works across all stages of five primary modalities: Biologics, Vaccines, Nucleic Acids, Cell Therapy and Gene Therapy.

Resilience offers several ways to engage, including incubation, collaboration, and manufacturing to support the development of 60+ molecules across its portfolio. The company’s offerings include Platform Technology & Development, Process & Analytical Development, and Clinical & Commercial Manufacturing, geared toward increasing access to medicines around the world and democratizing manufacturing.